Crescent Biopharma, Inc. SEC filings CBIO
Crescent Biopharma, Inc. has 676 filings in SEC EDGAR's recent list, going back to Jul 10, 2003. Its latest annual report, Form 10-K, was filed on Feb 26, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Jul 30, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 15, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Jul 31, 2026 | — |
| EFFECT | Filing | Jul 10, 2026 | — |
| EFFECT | Filing | Mar 3, 2026 | — |
| EFFECT | Filing | Jan 15, 2026 | — |
| CORRESP | Letter to the SEC | Jan 13, 2026 | — |
| UPLOAD | Letter from the SEC | Jan 12, 2026 | — |
| 8-A12B/A | Filing | Nov 6, 2025 | — |
| 425 | Filing | May 30, 2025 | — |
| 425 | Filing | May 29, 2025 | — |
| SEC STAFF LETTER | Filing | May 14, 2025 | — |
| EFFECT | Filing | May 14, 2025 | — |
| CORRESP | Letter to the SEC | May 13, 2025 | — |
| CORRESP | Letter to the SEC | May 12, 2025 | — |
| UPLOAD | Letter from the SEC | May 8, 2025 | — |
| 425 | Filing | Apr 29, 2025 | — |
| CORRESP | Letter to the SEC | Apr 28, 2025 | — |
| 425 | Filing | Apr 28, 2025 | — |
| UPLOAD | Letter from the SEC | Apr 22, 2025 | — |
| CORRESP | Letter to the SEC | Apr 4, 2025 | — |
| CORRESP | Letter to the SEC | Apr 4, 2025 | — |
| 425 | Filing | Apr 3, 2025 | — |
| 425 | Filing | Apr 3, 2025 | — |
| SEC STAFF LETTER | Filing | Mar 18, 2025 | — |
| UPLOAD | Letter from the SEC | Mar 17, 2025 | — |
| 425 | Filing | Feb 28, 2025 | — |
| 425 | Filing | Feb 27, 2025 | — |
| 425 | Filing | Feb 25, 2025 | — |
| 425 | Filing | Feb 14, 2025 | — |
| EFFECT | Filing | Apr 22, 2022 | — |
| CORRESP | Letter to the SEC | Apr 20, 2022 | — |
| UPLOAD | Letter from the SEC | Mar 10, 2022 | — |
| EFFECT | Filing | May 28, 2019 | — |
| CORRESP | Letter to the SEC | May 23, 2019 | — |
| UPLOAD | Letter from the SEC | May 23, 2019 | — |
| EFFECT | Filing | Oct 6, 2017 | — |
| CORRESP | Letter to the SEC | Oct 5, 2017 | — |
| UPLOAD | Letter from the SEC | Oct 5, 2017 | — |
| EFFECT | Filing | Mar 24, 2015 | — |
| CT ORDER | Filing | Jan 14, 2014 | — |
| POS EX | Post-effective amendment no. 1 to form s-1 | Jan 10, 2014 | — |
| EFFECT | Filing | Jan 9, 2014 | — |
| CORRESP | Letter to the SEC | Jan 7, 2014 | — |
| CORRESP | Letter to the SEC | Jan 6, 2014 | — |
| CERTNAS | Auto-generated paper document | Nov 7, 2013 | — |
| 8-A12B | Form 8-a12b | Nov 5, 2013 | — |
| CORRESP | Letter to the SEC | Nov 5, 2013 | — |
| CORRESP | Letter to the SEC | Nov 5, 2013 | — |
| CORRESP | Letter to the SEC | Oct 23, 2013 | — |
| CORRESP | Letter to the SEC | Oct 18, 2013 | — |
| UPLOAD | Letter from the SEC | Oct 17, 2013 | — |
| UPLOAD | Letter from the SEC | Sep 19, 2013 | — |
| DRS | Filing | Aug 21, 2013 | — |
| D/A | Filing | Oct 27, 2010 | — |
| D | Filing | Nov 4, 2009 | — |
| D | Filing | Nov 4, 2009 | — |
| REGDEX | Auto-generated paper document | Jul 13, 2006 | — |
| REGDEX | Auto-generated paper document | Jul 10, 2003 | — |
Showing 57 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CBIO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Cayman Islands
- Headquarters
- Waltham, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1253689
- Former names
- GLYCOMIMETICS INC (until Jun 23, 2025)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.